Emergent BioSolutions Inc. (NYSE: EBS) has achieved a notable milestone with the U.S. Food and Drug Administration (FDA) approving the supplemental Biologics License Application (sBLA) for ACAM2000. The approval expands the vaccine’s indication to include the prevention of mpox, a development that comes at a critical juncture as mpox continues to spread globally, particularly across […]
Emergent BioSolutions’ Narcan nasal spray has secured over-the-counter (OTC) designation from the US Food and Drug Administration (FDA), becoming the first and only prescription strength naloxone nasal spray to receive the status in the country. Narcan Naloxone HCl nasal spray 4 mg is indicated for emergency treatment of opioid overdose, including illegal fentanyl, in the […]
Bavarian Nordic A/S will acquire two oral vaccines from Emergent BioSolutions for a total consideration of up to $380 million, to strengthen its position in the travel vaccines space. The acquisition is expected to help Bavarian Nordic expand its US commercial sales, marketing, and distribution network, as well as increased scale in additional European markets. […]
Emergent BioSolutions said that it has dosed the first participant in a phase 3 clinical trial of CHIKV VLP — the company’s single-dose chikungunya vaccine candidate. The American biopharma company will test the safety and immunogenicity of the investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine. According to Emergent BioSolutions, CHIKV VLP is the only […]